Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Daylight-Mediated Photodynamic Therapy With Methyl Aminolevulinate in Actinic Keratosis Treatment.

Demay SDJ, Sharma K, Sapra S, Sapra R, Sapra P.

J Cutan Med Surg. 2018 Jan 1:1203475417752367. doi: 10.1177/1203475417752367. [Epub ahead of print]

PMID:
29351725
2.

Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.

Zhang CC, Yan Z, Pascual B, Jackson-Fisher A, Huang DS, Zong Q, Elliott M, Fan C, Huser N, Lee J, Sung M, Sapra P.

Neoplasia. 2018 Jan;20(1):1-11. doi: 10.1016/j.neo.2017.10.008. Epub 2017 Nov 21.

3.

Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs.

Piscianz E, Cuzzoni E, Sharma R, Tesser A, Sapra P, Tommasini A.

Curr Med Chem. 2017 Sep 11. doi: 10.2174/0929867324666170911162331. [Epub ahead of print]

PMID:
28901270
4.

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate.

Puthenveetil S, He H, Loganzo F, Musto S, Teske J, Green M, Tan X, Hosselet C, Lucas J, Tumey LN, Sapra P, Subramanyam C, O'Donnell CJ, Graziani EI.

PLoS One. 2017 May 30;12(5):e0178452. doi: 10.1371/journal.pone.0178452. eCollection 2017.

5.
6.

Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.

McGinn OJ, Krishnan S, Bourquin JP, Sapra P, Dempsey C, Saha V, Stern PL.

Haematologica. 2017 Jun;102(6):1075-1084. doi: 10.3324/haematol.2016.158485. Epub 2017 Mar 24.

7.

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.

Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M, Hampl J, Lazetic S, Pulito V, Rosfjord E, Sun Y, King L, Barletta F, Betts A, Guffroy M, Falahatpisheh H, O'Donnell CJ, Stull R, Pysz M, Escarpe P, Liu D, Foord O, Gerber HP, Sapra P, Dylla SJ.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaag2611. doi: 10.1126/scitranslmed.aag2611.

PMID:
28077676
8.

Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography.

Giddabasappa A, Gupta VR, Norberg R, Gupta P, Spilker ME, Wentland J, Rago B, Eswaraka J, Leal M, Sapra P.

Mol Cancer Ther. 2016 Oct;15(10):2530-2540. Epub 2016 Jul 27.

9.

Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.

Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, Musto S, Clark T, Rago B, Koehn F, Veneziale R, Falahaptisheh H, Han X, Barletta F, Lucas J, Subramanyam C, O'Donnell CJ, Tumey LN, Sapra P, Gerber HP, Ma D, Graziani EI.

Bioconjug Chem. 2016 Aug 17;27(8):1880-8. doi: 10.1021/acs.bioconjchem.6b00291. Epub 2016 Jul 28.

PMID:
27412791
10.

Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

Gerber HP, Sapra P, Loganzo F, May C.

Biochem Pharmacol. 2016 Feb 15;102:1-6. doi: 10.1016/j.bcp.2015.12.008. Epub 2015 Dec 11. Review.

PMID:
26686577
11.

Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.

Shor B, Kahler J, Dougher M, Xu J, Mack M, Rosfjord E, Wang F, Melamud E, Sapra P.

Clin Cancer Res. 2016 Jan 15;22(2):383-94. doi: 10.1158/1078-0432.CCR-15-1166. Epub 2015 Aug 28.

12.

Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.

Leal M, Wentland J, Han X, Zhang Y, Rago B, Duriga N, Spriggs F, Kadar E, Song W, McNally J, Shakey Q, Lorello L, Lucas J, Sapra P.

Bioconjug Chem. 2015 Nov 18;26(11):2223-32. doi: 10.1021/acs.bioconjchem.5b00205. Epub 2015 Jul 16.

PMID:
26180901
13.

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.

Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, Aujay M, Fong S, Khandke K, Pulito V, Ernstoff E, Escarpe P, Bernstein J, Pysz M, Zhong W, Upeslacis E, Lucas J, Lucas J, Nichols T, Loving K, Foord O, Hampl J, Stull R, Barletta F, Falahatpisheh H, Sapra P, Gerber HP, Dylla SJ.

Clin Cancer Res. 2015 Sep 15;21(18):4165-73. doi: 10.1158/1078-0432.CCR-15-0695. Epub 2015 May 26.

14.

Dysplastic Nevus: Management by Canadian Dermatologists.

Sapra P, Rosen C, Siddha S, Lynde CW.

J Cutan Med Surg. 2015 Sep-Oct;19(5):457-63. doi: 10.1177/1203475415575234. Epub 2015 Apr 1. Review.

PMID:
25834273
15.

Evolving Strategies for Target Selection for Antibody-Drug Conjugates.

Damelin M, Zhong W, Myers J, Sapra P.

Pharm Res. 2015 Nov;32(11):3494-507. doi: 10.1007/s11095-015-1624-3. Epub 2015 Jan 15.

PMID:
25585957
16.

The next generation of antibody drug conjugates.

Mack F, Ritchie M, Sapra P.

Semin Oncol. 2014 Oct;41(5):637-52. doi: 10.1053/j.seminoncol.2014.08.001. Epub 2014 Aug 12. Review.

PMID:
25440608
17.

Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug Conjugate.

Hu G, Leal M, Lin Q, Affolter T, Sapra P, Bates B, Damelin M.

Mol Pharm. 2015 Jun 1;12(6):1730-7. doi: 10.1021/mp5006323. Epub 2014 Dec 9.

PMID:
25423493
18.

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.

Shor B, Gerber HP, Sapra P.

Mol Immunol. 2015 Oct;67(2 Pt A):107-16. doi: 10.1016/j.molimm.2014.09.014. Epub 2014 Oct 7. Review.

PMID:
25304309
19.

Antibody-drug conjugates: an emerging modality for the treatment of cancer.

Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O.

Ann N Y Acad Sci. 2014 Aug;1321:41-54. doi: 10.1111/nyas.12499. Review.

PMID:
25123209
20.

A general approach to site-specific antibody drug conjugates.

Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, Song F, DeGuzman MJ, Ensari S, Pinkstaff JK, Sullivan LM, Biroc SL, Cho H, Schultz PG, DiJoseph J, Dougher M, Ma D, Dushin R, Leal M, Tchistiakova L, Feyfant E, Gerber HP, Sapra P.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1766-71. doi: 10.1073/pnas.1321237111. Epub 2014 Jan 17.

21.

Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.

Sapra P, Betts A, Boni J.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):541-55. doi: 10.1586/17512433.2013.827405. Epub 2013 Aug 26. Review.

PMID:
23978126
22.

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.

Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM.

J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):557-71. doi: 10.1007/s10928-013-9329-x. Epub 2013 Aug 10.

PMID:
23933716
23.

Pearly penile papules: effective therapy with pulsed dye laser.

Sapra P, Sapra S, Singh A.

JAMA Dermatol. 2013 Jun;149(6):748-50. doi: 10.1001/jamadermatol.2013.3130.

PMID:
23752333
24.

Monoclonal antibody-based therapies in cancer: advances and challenges.

Sapra P, Shor B.

Pharmacol Ther. 2013 Jun;138(3):452-69. doi: 10.1016/j.pharmthera.2013.03.004. Epub 2013 Mar 15. Review.

PMID:
23507041
25.

Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.

Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, Dougher M, Narayanan B, Giannakou A, Khandke K, Dushin R, Ernstoff E, Lucas J, Leal M, Hu G, O'Donnell CJ, Tchistiakova L, Abraham RT, Gerber HP.

Mol Cancer Ther. 2013 Jan;12(1):38-47. doi: 10.1158/1535-7163.MCT-12-0603. Epub 2012 Dec 5.

26.

Advances in bispecific biotherapeutics for the treatment of cancer.

May C, Sapra P, Gerber HP.

Biochem Pharmacol. 2012 Nov 1;84(9):1105-12. doi: 10.1016/j.bcp.2012.07.011. Epub 2012 Jul 25. Review.

PMID:
22858161
27.

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.

Zhang Y, Castaneda S, Dumble M, Wang M, Mileski M, Qu Z, Kim S, Shi V, Kraft P, Gao Y, Pak J, Sapra P, Bandaru R, Zhao H, Vessella RL, Horak ID, Greenberger LM.

Mol Cancer Ther. 2011 Dec;10(12):2309-19. doi: 10.1158/1535-7163.MCT-11-0329. Epub 2011 Oct 25.

28.

Investigational antibody drug conjugates for solid tumors.

Sapra P, Hooper AT, O'Donnell CJ, Gerber HP.

Expert Opin Investig Drugs. 2011 Aug;20(8):1131-49. doi: 10.1517/13543784.2011.582866. Epub 2011 May 23. Review.

PMID:
21599617
29.

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.

Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, Mehlig M, Wang M, Ponzoni M, Greenberger LM, Horak ID.

Angiogenesis. 2011 Sep;14(3):245-53. doi: 10.1007/s10456-011-9209-1. Epub 2011 Mar 31.

30.

Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.

Pastorino F, Loi M, Sapra P, Becherini P, Cilli M, Emionite L, Ribatti D, Greenberger LM, Horak ID, Ponzoni M.

Clin Cancer Res. 2010 Oct 1;16(19):4809-21. doi: 10.1158/1078-0432.CCR-10-1354. Epub 2010 Aug 11.

31.

Impact of evolving strategy on clinical outcomes and central pulmonary artery growth in patients with bilateral superior vena cava undergoing a bilateral bidirectional cavopulmonary shunt.

Honjo O, Tran KC, Hua Z, Sapra P, Alghamdi AA, Russell JL, Caldarone CA, Van Arsdell GS.

J Thorac Cardiovasc Surg. 2010 Sep;140(3):522-8, 528.e1. doi: 10.1016/j.jtcvs.2010.04.036.

32.

Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide.

Sapra P, Wang M, Bandaru R, Zhao H, Greenberger LM, Horak ID.

Nucleosides Nucleotides Nucleic Acids. 2010 Feb;29(2):97-112. doi: 10.1080/15257771003597733.

PMID:
20391197
33.

Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.

Sapra P, Kraft P, Mehlig M, Malaby J, Zhao H, Greenberger LM, Horak ID.

Haematologica. 2009 Oct;94(10):1456-9. doi: 10.3324/haematol.2009.008276.

35.

Segmented approach for China and India.

Bhattacharjya AS, Sapra PK.

Health Aff (Millwood). 2009 Mar-Apr;28(2):606. doi: 10.1377/hlthaff.28.2.606. No abstract available.

PMID:
19276041
36.

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.

Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, Albaek C, Schrøder H, Ørum H.

Mol Cancer Ther. 2008 Nov;7(11):3598-608. doi: 10.1158/1535-7163.MCT-08-0510. Epub 2008 Oct 30.

37.

Health insurance in China and India: segmented roles for public and private financing.

Bhattacharjya AS, Sapra PK.

Health Aff (Millwood). 2008 Jul-Aug;27(4):1005-15. doi: 10.1377/hlthaff.27.4.1005.

PMID:
18607034
38.

Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.

Zhao H, Rubio B, Sapra P, Wu D, Reddy P, Sai P, Martinez A, Gao Y, Lozanguiez Y, Longley C, Greenberger LM, Horak ID.

Bioconjug Chem. 2008 Apr;19(4):849-59. doi: 10.1021/bc700333s. Epub 2008 Mar 28.

PMID:
18370417
39.

Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.

Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, Greenberger LM, Horak ID.

Clin Cancer Res. 2008 Mar 15;14(6):1888-96. doi: 10.1158/1078-0432.CCR-07-4456.

40.

Ligand-targeted liposomes for cancer treatment.

Sapra P, Tyagi P, Allen TM.

Curr Drug Deliv. 2005 Oct;2(4):369-81. Review.

PMID:
16305440
41.

Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin.

Chang CH, Sapra P, Vanama SS, Hansen HJ, Horak ID, Goldenberg DM.

Blood. 2005 Dec 15;106(13):4308-14. Epub 2005 Aug 18.

42.

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.

Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM.

Clin Cancer Res. 2005 Jul 15;11(14):5257-64.

43.

Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.

Sapra P, Allen TM.

Clin Cancer Res. 2004 Apr 1;10(7):2530-7. Erratum in: Clin Cancer Res. 2004 Jul 15;10(14);4893.

45.

Ligand-targeted liposomal anticancer drugs.

Sapra P, Allen TM.

Prog Lipid Res. 2003 Sep;42(5):439-62. Review.

PMID:
12814645
46.

Adventures in targeting.

Allen TM, Sapra P, Moase E, Moreira J, Iden D.

J Liposome Res. 2002 Feb-May;12(1-2):5-12.

PMID:
12604033
47.

Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.

Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M.

Cancer Res. 2003 Jan 1;63(1):86-92.

48.
49.

Use of the post-insertion method for the formation of ligand-coupled liposomes.

Allen TM, Sapra P, Moase E.

Cell Mol Biol Lett. 2002;7(3):889-94.

PMID:
12378272
50.

Use of the post-insertion method for the formation of ligand-coupled liposomes.

Allen TM, Sapra P, Moase E.

Cell Mol Biol Lett. 2002;7(2):217-9. No abstract available.

PMID:
12097921

Supplemental Content

Support Center